Need professional-grade analysis? Visit stockanalysis.com
$729.60M
N/A
N/A
N/A
Price Chart
Risk-Adjusted Performance
Kura Oncology Inc (KURA) Price Performance
Kura Oncology Inc (KURA) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $8.07, down 2.30% from the previous close.
Over the past year, KURA has traded between a low of $5.54 and a high of $12.14. The stock has gained 13.3% over this period. It is currently 33.5% below its 52-week high.
Kura Oncology Inc has a market capitalization of $729.60M.
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Company Info
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Exchange
- United States
- Currency
- USD
- Country
- United States
Financial Metrics
- Revenue (TTM)
- $67.48M
- EBITDA
- $-302,599,008
- Profit Margin
- -322.89%
- EPS (TTM)
- -3.18
- Book Value
- 1.98
Technical Indicators
- 52 Week High
- $12.49
- 52 Week Low
- $5.41
- 50 Day MA
- $8.65
- 200 Day MA
- $8.46
- Beta
- 0.22
Valuation
- Trailing P/E
- N/A
- Forward P/E
- -3.68
- Price/Sales
- 10.81
- Price/Book
- 4.17
- Enterprise Value
- $82.82M